Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13251374 | 0.83 | CXCR4 (0.50) | CXCR4SIGMAR1SMN1; SMN2POLBCHRM5 | |
| Hydrochloric Acid SCHEMBL27423153 | 0.82 | CXCR4 (0.48) | CXCR4SIGMAR1SMN1; SMN2POLBCHRM5 | |
| SCHEMBL23542110 | 0.80 | CXCR4 (0.47) | CXCR4SIGMAR1SMN1; SMN2POLBCHRM5 | |
| SCHEMBL8460966 | 0.80 | CXCR4 (0.47) | CXCR4SIGMAR1SMN1; SMN2POLBCHRM5 | |
| SCHEMBL20333414 | 0.78 | CXCR4 (0.46) | CXCR4SIGMAR1SMN1; SMN2POLBCHRM5 | |
| SCHEMBL11932527 | 0.78 | CXCR4 (0.52) | CXCR4SIGMAR1SMN1; SMN2POLBCHRM5 | |
| SCHEMBL26940040 | 0.77 | CXCR4 (0.44) | CXCR4SIGMAR1SMN1; SMN2POLBCHRM5 | |
| SCHEMBL14944015 | 0.76 | CXCR4 (0.55) | CXCR4SIGMAR1SMN1; SMN2POLBCHRM5 | |
| SCHEMBL21016068 | 0.76 | CXCR4 (0.55) | CXCR4SIGMAR1SMN1; SMN2POLBCHRM5 | |
| SCHEMBL1408782 | 0.75 | CXCR4 (0.50) | CXCR4SIGMAR1SMN1; SMN2POLBCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772319-B2 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120208847-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-8114379-B2 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | THE GENERAL HOSPITAL CORPORATION (US) | 2009-07-30 | — | — | US | disclosed |
| US-7381822-B2 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION (US) | 2008-06-03 | — | — | US | disclosed |
| US-20050222166-A1 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
| WO-2004063150-A2 | DIAGNOSTIC AND THERAPEUTIC ALKYL PIPERIDINE/PIPERAZINE COMPOUNDS AND PROCESS | THE GENERAL HOSPITAL CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222166-A1 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | HCRTR1, NR2E3, CHRNA3 | CXCR4 409/4885SIGMAR1 16/4885SMN1; SMN2 209/4885 |
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | NR2E3, DRD2, HCRTR1 | CXCR4 485/4885SIGMAR1 16/4885SMN1; SMN2 206/4885 |
| US-20120208847-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | SNCA, NLN, DRD2 | CXCR4 3196/4885SIGMAR1 521/4885SMN1; SMN2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.